VFVictoria Forbes

Victoria Forbes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Victoria Forbes has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cancer Among Asian Americans and Pacific Islanders, 1999–2020

    by Jia Yi Tan, Xuan Ci Mee, Wan Ying Tan, Gunwant Guron, Victoria Elizabeth Forbes

    Asian Americans and Pacific Islanders are among the fastest-growing racial groups in the United States but remain underrepresented in cancer research, leading to gaps in understanding their cancer risks and outcomes. This study examines cancer mortality trends among Asian Americans and Pacific Islanders from 1999 to 2020 using Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) data. Age-adjusted mortality rates (AAMR) per 100,000 individuals and average annual percent change (AAPC) were analyzed with Joinpoint Regression. Overall cancer AAMR significantly declined from 188.68 (95% Confidence Interval [CI], 184.49–192.88) to 138.85 (95% CI, 136.9–140.8) per 100,000 individuals, with an AAPC of -1.44 (95% CI, -1.53, -1.34). Lung cancer (21.94%), colon cancer (7.40%), and pancreatic cancer (7.09%) were the leading causes of cancer death. Men had higher AAMR than women (188.75 [95% CI, 187.78—189.72] vs. 136.01 [95% CI, 135.31—136.71] per 100,000 individuals). The highest AAMR were observed in the West (172.95 [95% CI, 172.16—173.74] per 100,000 individuals) and rural areas (175.34 [95% CI, 172.00—178.68] per 100,000 individuals). Despite declining mortality, Asian Americans and Pacific Islanders experienced slower reductions in mortality compared to other racial groups, with disparities persisting across sex, geography, and urbanization. Targeted prevention efforts, improved screening, and culturally tailored interventions are essential to address these gaps and improve outcomes.


  • Conflict and Access to Health Care

    by Victoria Forbes, Dafina Ademi Islami, Ilir Hoxha


  • Education and Training Models for Remote Learning

    by Victoria E. Forbes, Mary D. Chamberlin, Vincent Dusabejambo, Tim Walker, Steve P. Bensen, Norrisa Haynes, Kathryn Nunes, Veauthyelau Saint-Joy, Frederick L. Makrauer


  • Open Access

    Concurrent Lymphoma and COVID-19: Diagnostic and Therapeutic Challenges of High-Grade Lymphoma and COVID-19

    by Jasmin Hundal, Alexander R. Vartanov, Kang Huh, Enrique Ballesteros, Victoria Forbes

    The coronavirus disease 2019 (COVID-19) global pandemic has put an unprecedented strain on cancer care. The initial months were marred by fears of immunocompromised patients becoming opportunistic hosts to this deadly virus. We present a case of newly diagnosed high-grade B-cell lymphoma in a patient with COVID-19 and discuss the diagnostic and therapeutic challenges posed. A 76-year-old female presented with one month of progressive malaise, poor appetite, weight loss, and night sweats. A surveillance COVID-19 polymerase chain reaction (PCR) resulted positive. With strict isolation precautions, the daily focused physical examination masked several key findings including multifocal adenopathy. She developed hypoxic respiratory failure and progressive transaminitis and cytopenias. Image-guided, rather than excisional, biopsy revealed high-grade B-cell lymphoma. Superimposed COVID-19 infection presented multiple challenges, but she completed treatment and achieved remission. Suspicion for underlying malignancy was high. Institutional concerns included obtaining imaging studies and the gold standard excisional tissue biopsy while maintaining acceptable staff exposure. Fortunately, a lymph node core biopsy confirmed the histopathological diagnosis of high-grade B-cell lymphoma. The administration of chemoimmunotherapy (rituximab, cyclophosphamide, doxorubicin, dose-reduced vincristine, and prednisone (R-CHOP)) posed inherent risks, notably, worsening cytopenias and hepatotoxicity. The approach to treatment was further complicated as the interaction of high-grade lymphoma and COVID-19 remained unclear. Medical teams have faced delays executing formerly routine diagnostic studies and formulating timely and appropriate treatment strategies. Careful consideration of risks and benefits must be weighed. A multidisciplinary approach is crucial to successfully treat patients. The relationship between COVID-19 and cancer treatment is yet to be established, and large sample-size studies are required.